FDA clears first device treatment for childhood ADHD

FDA
NeuroSigma's Monarch system previously received CE marks for ADHD in adults and children over age 7, and in major depressive disorder in patients older than 9. (FDA)

The FDA has cleared the first medical device for treating attention deficit hyperactivity disorder (ADHD): an at-home nerve stimulation system designed for children ages 7 to 12.

The prescription-only treatment—NeuroSigma’s Monarch external trigeminal nerve stimulation system—is designed for children who are currently not taking any medications. About the size of a cellphone, the device delivers a mild electrical pulse to a wired patch placed on the patient’s forehead while sleeping.

By stimulating the branches of the trigeminal cranial nerve, it is believed the system triggers therapeutic signals sent to the parts of the brain involved in ADHD, although the exact mechanism is not known. Neuroimaging studies have shown that eTNS increases brain activity in regions related to attention, emotion and behavior, according to the FDA.

Webinar

De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

There is a high attrition rate during the development of biotherapeutics impacting the high cost of development. Early identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to reduce both attrition rates and cost.

“This new device offers a safe, non-drug option for treatment of ADHD in pediatric patients through the use of mild nerve stimulation, a first of its kind,” said Carlos Peña, director of the Division of Neurological and Physical Medicine Devices in the FDA’s Center for Devices and Radiological Health, which granted the device a de novo clearance.

In a placebo-controlled clinical trial of 62 children, the Monarch system demonstrated significant improvements in an ADHD symptom scale after four weeks. According to the FDA, it may take at least one month for the treatment to deliver a noticeable effect; after that time, caregivers should consult their providers to reassess the treatment.

While no serious adverse events were observed, the most common side effects were drowsiness, an increase in appetite, trouble sleeping, teeth clenching, headache and fatigue. The device should not be used in patients with implanted pacemakers or neurostimulators, nor wearable insulin pumps.

The Los Angeles-based NeuroSigma previously received a CE mark for its device in late 2015 for use in adults and children over age 7, representing the first nondrug ADHD treatment in the EU. The Monarch system has also received a CE mark in major depressive disorder in patients older than 9.

Suggested Articles

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.

Novavax has brought new CMC head Machielse to head manufacturing; Rexgenero taps Wagener as CMO; EMA nominates Cooke as new director.

The deal grants Sarepta the exclusive right to use Hansa Biopharma’s imlifidase to eliminate neutralizing antibodies in DMD and LGMD patients.